NCT04850183

Brief Summary

This randomized controlled study aimed to determine the effect of education on disease management on the quality of life, and anxiety and depression levels of women with Rheumatoid Arthritis. The hypotheses of the current study are as below: H0: Education on disease management in women with Rheumatoid Arthritis does not affect the quality of life and anxiety and depression levels. H1: Education on disease management in women with Rheumatoid Arthritis affects the quality of life and anxiety and depression levels. Patients and Methods: The study was conducted with 66 women with Rheumatoid Arthritis (32 intervention, 34 control groups) at the rheumatology clinic and polyclinic of a university hospital between February and October 2019, in the city of Edirne, Turkey. Data were collected with "Patient Information Form", "Rheumatoid Arthritis Quality of Life Scale", "Health Assessment Questionnaire" and "Hospital Anxiety Depression Scale".

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
66

participants targeted

Target at P25-P50 for not_applicable rheumatoid-arthritis

Timeline
Completed

Started Mar 2019

Shorter than P25 for not_applicable rheumatoid-arthritis

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 4, 2019

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 6, 2020

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 26, 2020

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

April 14, 2021

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 20, 2021

Completed
Last Updated

April 20, 2021

Status Verified

April 1, 2021

Enrollment Period

1 year

First QC Date

April 14, 2021

Last Update Submit

April 18, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change from baseline Rheumatoid Arthritis Quality of Life Questionnaire in the third month

    The questionnaire consists of 30 questions, each with a score of "yes" = 1 or "no" = 0. The scores ranged from 0 to 30, with high scores showing poor quality of life.

    Patients' quality of life assess at baseline and in the third month.

Secondary Outcomes (2)

  • Change from baseline Hospital Anxiety and Depression Scale (HADS) in the third month

    Patients' HADS scores assess at baseline and in the third month.

  • Change from baseline Stanford Health Assessment Questionnaire (HAQ) in the third month

    Patients' HAQ score assess at baseline and the third month.

Study Arms (2)

Intervention group

EXPERIMENTAL

Patients were interviewed twice, at baseline and at the 3rd month. All forms were applied to the patients in the intervention group at baseline. The patients were assigned to the intervention group at random and participated in a one-to-one training program consisting of a 30-min onset session. The Rheumatoid Arthritis Patient Education Booklet prepared by the researchers was administered to patients in the intervention group during education. In the 3rd month, all forms were applied again to the patients in the intervention group.

Behavioral: Education on disease management on the quality of life, and anxiety and depression about Rheumatoid Arthritis

Control group

NO INTERVENTION

Patients were interviewed twice, at baseline and at the 3rd month. All forms were applied to the patients in the control group at baseline. In the 3rd month, the same forms were applied to the untrained patients in the control group.

Interventions

The patients in the intervention group participated in a one-to-one training program consisting of a 30-min onset session.

Intervention group

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsThe prevalence of Rheumatoid Arthritis prevalence is three times higher in women than in men.
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • To be female
  • years of age and older
  • Diagnosed with Rheumatoid Arthritis who reached the 2010 American College of Rheumatology (ACR) criterion
  • Had a disease period of at least 6 months

You may not qualify if:

  • Other serious and chronic mental disorders
  • Communication difficulties
  • Illiteracy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Trakya University

Edirne, 22030, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Arthritis, RheumatoidDepressionAnxiety Disorders

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System DiseasesBehavioral SymptomsBehaviorMental Disorders

Study Officials

  • Irem Yildiz Cilengiroglu

    Trakya University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
SUPPORTIVE CARE
Intervention Model
FACTORIAL
Model Details: intervention group and control group
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

April 14, 2021

First Posted

April 20, 2021

Study Start

March 4, 2019

Primary Completion

March 6, 2020

Study Completion

June 26, 2020

Last Updated

April 20, 2021

Record last verified: 2021-04

Data Sharing

IPD Sharing
Will not share

Locations